Fairfield, Bush & Co. Gilead Sciences, Inc. Transaction History

Fairfield, Bush & Co.

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $9,232 - $10,469	126 New	126 $10.2 Million
Q2 2023 Aug 15, 2023	BUY	$76.01 - $86.7 $9,577 - $10,924	126 New	126 $9.71 Million
Q2 2022 Aug 09, 2022	SELL	$57.72 - $65.01 $5,079 - $5,720	-88 Reduced 48.89%	92 $6,000
Q1 2022 May 06, 2022	BUY	$57.92 - $72.58 $10,425 - $13,064	180 New	180 $11,000
Q3 2021 Nov 08, 2021	SELL	$67.69 - $73.03 $390,503 - $421,310	-5,769 Closed	0 $0
Q2 2021 Aug 02, 2021	SELL	$63.47 - $69.35 $225,255 - $246,123	-3,549 Reduced 38.09%	5,769 $397,000
Q1 2021 May 14, 2021	BUY	$60.0 - $68.46 $43,800 - $49,975	730 Added 8.5%	9,318 $602,000
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $439,660 - $500,972	-7,761 Reduced 47.47%	8,588 $500,000
Q3 2020 Nov 18, 2020	BUY	$62.1 - $78.08 $24,840 - $31,232	400 Added 2.51%	16,349 $1.03 Million
Q2 2020 Aug 13, 2020	BUY	$72.34 - $84.0 $165,079 - $191,688	2,282 Added 16.7%	15,949 $1.23 Million
Q1 2020 May 13, 2020	BUY	$62.63 - $80.22 $497,908 - $637,749	7,950 Added 139.06%	13,667 $1.02 Million
Q4 2019 Feb 12, 2020	SELL	$61.62 - $67.78 $6,285 - $6,913	-102 Reduced 1.75%	5,717 $371,000
Q2 2019 Aug 13, 2019	BUY	$61.87 - $69.38 $1,051 - $1,179	17 Added 0.29%	5,819 $393,000
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $25,012 - $28,020	400 Added 7.4%	5,802 $377,000
Q2 2018 Aug 16, 2018	BUY	$64.88 - $75.68 $778 - $908	12 Added 0.22%	5,402 $383,000
Q4 2017 Feb 22, 2018	SELL	$71.15 - $83.52 $23,123 - $27,144	-325 Reduced 5.69%	5,390 $386,000
Q2 2017 Aug 15, 2017	BUY	N/A	5,715	5,715 $405,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

Stay updated on Fairfield, Bush & Co. with notifications on news.